Agennix Moves Novel Dendritic Cell Activator Into Phase III For Non-Small Cell Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Trials begin once the company completes a financing round, CEO Barsky tells "The Pink Sheet" DAILY.